The results of clinical research using Kortuc in treatment for locally advanced or recurrent breast cancer by Dr. Taiju Shimbo, Radiation Oncologist in Osaka Medical College, were published in Molecular and Clinical Oncology on September 24, 2021.
These results show that radiation therapy using Kortuc achieved a median maximum tumor shrinkage of 97%, and half of the patients were assessed to have achieved a clinical complete response.
Kazu Matsuda, CEO of KORTUC, commented “I am excited that Kortuc has demonstrated excellent efficacy in locally advanced or recurrent breast cancer and expect the ongoing pivotal Phase 2 study in the UK will have a promising outcome”.
KORTUC is developing the first ever proprietary technology to counter hypoxia – a common problem that for decades has blunted the efficacy of radiation therapy for cancer. The technology has a high safety/efficacy profile as demonstrated by a Phase 1 study at the Royal Marsden Hospital in the UK and more than 1,000 clinical cases in Japan.
Through this technology platform, KORTUC will bring about a paradigm shift in cancer treatment by improving radiotherapy and immunotherapy.
Further information can be found below
- Abstract and full text of Dr. Shimbo’s article are available here
- Pivotal Phase 2 study
- Technology of Kortuc